In addition, Revelar will have the ability to leverage the antibody discovery and optimization platform of Twist Biopharma to license additional antibodies for up to five targets over the next four years.
Twist Bioscience granted a license to Revelar for the exclusive development of an antibody lead along with a series of back up compounds for the potential treatment of SARS-CoV-2.
Twist may receive success-based milestone payments totaling over USD 100m for the achievement of key development, regulatory and commercial milestones, as well as mid-single digit royalties on any future net sales.
In addition, Revelar may license up to five additional antibody therapeutics over the next four years, each of which will be subject to additional upfront, milestone and royalty payments to Twist.
Twist has committed to invest up to USD 10m in seed funding based on Revelar's progress in the development of the lead antibody and the potential licensing of additional antibody therapeutics.
In exchange for its cash investment, the antibody, and its back-up compounds, Twist received significant minority ownership in Revelar.
Revelar's executive leadership team includes Glenn Marina, Kevin Malobisky (chief regulatory and quality officer), Laurence Smith (CFO and general counsel), and Rodrigo Mesquita (vice president of operations and project management).
The board will be comprised of David Scheer (chairman), Paul Fonteyne, Brett Giroir, Emily Leproust (Twist Bioscience's CEO and co-founder) and Patrick Finn (Twist Bioscience's chief commercial officer).
Revelar Biotherapeutics is a biopharmaceutical company focused on developing and commercializing breakthrough therapeutic antibody products that address critical unmet patient needs for COVID-19 and other therapeutic areas.
The management team of Revelar Biotherapeutics has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations with leading global pharmaceutical companies.
The company's therapeutic areas of interest include oncology, autoimmune disorders, and infectious diseases.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer